Israel Englander’s Millennium Management more than doubled its holdings in AbbVie and Costco, signaling long-term confidence in the dividend-paying giants' growth potential and market stability.
AbbVie is attracting institutional interest, including from Millennium Management, due to its strong revenue growth driven by immunology blockbusters Skyrizi and Rinvoq. The company has successfully mitigated patent cliff concerns through the end of the decade and is expanding its pipeline with promising assets like the weight-loss candidate ABBV-295 and the acquisition of Apogee Therapeutics. Furthermore, its status as a Dividend King provides a reliable income stream that appeals to long-term investors.
No, the company has no remaining significant patent cliffs through the end of the current decade.
AbbVie has achieved over 50 consecutive years of payout increases, including the time it spent as a division of Abbott Laboratories.
Despite a volatile macroeconomic environment and a high valuation relative to consumer staples, Costco continues to demonstrate financial resilience with double-digit revenue and earnings growth. Its subscription-based business model creates a high-margin, recurring revenue stream that fosters customer loyalty, while its expanding e-commerce segment provides a long-term tailwind for profitability. Millennium Management's decision to double its stake reflects confidence in these durable competitive advantages.
Costco has raised its payouts for 22 consecutive years.
Investors pay a premium due to the company's resilient subscription model, which provides recurring revenue and high customer retention.
Hedge fund giant Millennium Management, led by Israel Englander, significantly increased its positions in AbbVie and Costco during the second quarter. Both companies are recognized for their robust dividend growth and resilient business models, despite facing distinct market headwinds and valuation pressures.
The firm is betting on AbbVie's solid immunology pipeline, consistent dividend growth as a Dividend King, and the potential of new weight-loss and dermatology candidates.
While Costco trades at a premium compared to other consumer staples, its resilient subscription-based revenue model and consistent earnings growth support its long-term investment appeal.